• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

C-Rad

37.40 SEK+1.08 %15.7. klo 18.25
Less than 1K followers

CRAD B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.08 %
+3.89 %
+38.52 %
+14.90 %
+17.06 %
+9.04 %
+34.05 %
-37.56 %
+188.03 %

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

Read more
Market cap
1.26B SEK
Turnover
419.31K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

22.10.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Regulatory press release15.05.2026 klo 10.00

C-RAD and SeeTreat partner to deliver personalised radiotherapy for every patient

C-Rad
Press release13.05.2026 klo 10.00

C-RAD marks its new chapter at ESTRO 2026 with clinician-driven SGRT advances

C-Rad
Regulatory press release06.05.2026 klo 09.00

C-RAD's Interim Report Q1’26

C-Rad

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release10.04.2026 klo 16.00

C-RAD publishes its annual report for 2025

C-Rad
C-RAD, Audiocast, Q4'25
Webcast12.02.2026 klo 12.00

C-RAD, Audiocast, Q4'25

C-Rad
Regulatory press release12.02.2026 klo 09.00

C-RAD's Year-end report Q4'25

C-Rad
Press release29.01.2026 klo 09.00

Invitation to presentation of C-RAD’s year-end report and report for the fourth quarter 2025

C-Rad
Regulatory press release26.01.2026 klo 15.25

Tomas Blomquist appointed new CEO of C-RAD

C-Rad
C-RAD, Audiocast, Q3'25
Webcast23.10.2025 klo 12.00

C-RAD, Audiocast, Q3'25

C-Rad
Regulatory press release22.10.2025 klo 18.55

C-RAD has decided to repurchase own class B shares

C-Rad
Regulatory press release21.10.2025 klo 20.00

C-RAD ABs Interim Report Q3 2025

C-Rad
Press release21.10.2025 klo 19.20

C-RAD advances approval of interim report for Q3 2025

C-Rad
Regulatory press release21.10.2025 klo 19.15

C-RAD's CEO leaves, CFO Linda Frölén appointed acting CEO, Johan Danielsson is appointed deputy CEO

C-Rad
Press release09.10.2025 klo 09.00

Invitation to presentation of C-RAD’s interim report and report for the third quarter 2025

C-Rad
Press release30.09.2025 klo 10.00

C-RAD Strengthens Czech Presence with a strategically important order from Krajská Nemocnice Hospital in Liberec.

C-Rad
Press release26.09.2025 klo 11.00

C-RAD showcases new developments at ASTRO 2025

C-Rad
Regulatory press release28.07.2025 klo 09.00

C-RAD and iRT Systems announce partnership to advance safety in radiotherapy

C-Rad
C-RAD, Audiocast, Q2'25
Webcast18.07.2025 klo 12.00

C-RAD, Audiocast, Q2'25

C-Rad
Regulatory press release18.07.2025 klo 09.00

C-RAD AB's Interim Report Q2 2025

C-Rad
Press release04.07.2025 klo 10.30

C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider

C-Rad